Onl Therapeutics Is A Clinical Stage Biopharmaceutical Company Dedicated To Developing Neuroprotective Therapies For Retinal Diseasesthe Company Focuses On Preventing Vision Loss By Targeting Fas Mediated Cell Deatha Key Factor In Retinal Degenerationits Mission Is To Create Innovative Therapeutics That Protect And Improve Vision For Patients Suffering From Conditions With Limited Treatment Options The Lead Productonl1204Is A First In Class Small Peptide Fas Inhibitor Designed To Block Cell Death And Inflammatory Pathways In Retinal Cellsit Is Currently In Clinical Development For Several Applicationsincluding Retinal Detachmentage Related Macular Degenerationand Open Angle Glaucomaonl Therapeutics Has A Strong Intellectual Property Portfolio And Has Recently Secured $65 Million In Series D Financing To Support Its Clinical Programsthe Company Aims To Address The Needs Of Patients Affected By These Conditionsparticularly Those In Underserved Populations
No conferences found for this company.
| Company Name | Onl Therapeutics |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
